Generated: April 27, 2017
|Title:||Method of treating cholera|
|Abstract:||This invention discloses a method of treating cholera infection in a human by administering an effective amount of 1,5-dideoxy-1,5-imino-D-glucitol or a derivative thereof.|
|Inventor(s):||Platt; Frances M. (Oxford, GB), Neises; Gabrielle R. (Chesterfield, MO), Dwek; Raymond A. (Oxford,, GB), Butters; Terry D. (Oxford,, GB)|
|Assignee:||Monsanto Company (St. Louis, MO)|
|Filing Date:||May 13, 1993|
|Claims:||1. A method of treating cholera in a human in need thereof comprising administering to said human a therapeutically effective amount of an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol in which said alkyl contains from 2-8 carbon atoms. |
2. The method of claim 1 in which the alkyl group contains from 4-6 carbon atoms.
3. The method of claim 1 in which the alkyl group is butyl.
4. The method of claim 1 in which the alkyl group is hexyl.
5. The method of claim 1 in which the therapeutically effective amount is from about 1 mg to about 100 mg per day.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.